"Isotretinoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.
| Descriptor ID |
D015474
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.325 D02.455.426.392.368.367.379.249.700.325 D02.455.849.131.495.325 D23.767.261.700.325
|
| Concept/Terms |
Isotretinoin- Isotretinoin
- 13-cis-Retinoic Acid
- 13 cis Retinoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Isotretinoin".
Below are MeSH descriptors whose meaning is more specific than "Isotretinoin".
This graph shows the total number of publications written about "Isotretinoin" by people in this website by year, and whether "Isotretinoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isotretinoin" by people in Profiles.
-
Evaluating the Readability of the iPledge Comprehension Assessment and its Impact on Isotretinoin Accessibility. Pediatr Dermatol. 2025 Mar-Apr; 42(2):413-414.
-
Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022; 33(1):65-76.
-
A Case of Myelofibrosis and Myelodysplasia Identified Following Exposure to Isotretinoin. J Pediatr Hematol Oncol. 2021 01; 43(1):e136-e137.
-
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer. 2020 08; 123(4):568-579.
-
Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017 08 01; 153(8):802-809.
-
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87.
-
Congenital neuroblastoma in a neonate with isotretinoin embryopathy. J Pediatr Hematol Oncol. 2014 Mar; 36(2):e75-7.
-
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
-
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
-
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.